Monoclonal Antibody Market: Global and China Market Analysis, Industry Size, Share, Growth, Trends and Forecsat Report 2014-2019 Available Online by MarketResearchReports

Market Research Reports.Biz include new market research report "Global And China Monoclonal Antibody Industry Report 2014-2019" to its huge collection of research reports.


Albany, NY -- (SBWIRE) -- 10/29/2014 -- Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biotech drugs with the fastest CAGR in recent years.

View Full Report

Global blockbuster monoclonal antibody agents are still concentrated in Roche (Genentech), Amgen, AbbVie (Abbott), Johnson & Johnson, Novartis, etc. In 2013, the top 10 best-selling monoclonal antibody agents (Humira, Remicade, Enbrel, Rituxa, Avastin, Herceptin, Lucents, Synagis, Prolia/Xgeva and Erbitux, in order) mostly came from these companies mentioned above. Global sales of these ten monoclonal antibody agents totaled about USD 58.1 billion in 2013, and are predicted to amount to USD 64.1 billion in 2014.

These companies construct mature monoclonal antibody R&D platform, have unparalleled technical advantages in a series of processes including the selection of target gene, genetic sequencing, construction of monoclonal antibody structure and industrialized production, and are well-capitalized (R&D costs of these companies accounted for 15%-20% of revenue during the same period.). It is expected that they will keep a leading position in global monoclonal antibody market over the next five to ten years.

Download Detail Report With Complete TOC

In Sept. 2014, Opdivo (nivolumab) of Bristol-Myers Squibb was accepted for priority review by FDA and EMA. The indication of the drug is unresectable or metastatic melanoma. In the same month, KEYTRUDA (pembrolizumab) under Merck became the first FDA-approved Anti-PD-1 therapy, which can be used for advanced melanoma.

In Apr. 2014, Janssen under Johnson & Johnson announced the FDA had approved SYLVANT (siltuximab) for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Lilly's CYRAMZA (ramucirumab) became first FDA-approved treatment for with advanced gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior chemotherapy.

Browse All Published Reports by Research in China

The Chinese monoclonal antibody market developed rapidly in recent years, with market size recording a CAGR of 38.9% during 2010-2013. There are nine domestic monoclonal antibody agents introduced to the market, such as Shanghai CP Guojian Pharmaceutical’s Nimotuzuma and Biotech Pharm’s recombinant humanized anti-CD25 monoclonal antibody. However, the market is dominated by imported agents like Rituximab, Trastuzumab, Infliximab and Bevacizumab, which account for more than 70%.

However, in Aug. 2014, Hisun Pharm received notice from SFDA on applying for production field inspection for Recombinant Human Tumor Necrosis Factor Receptor Type II - Antibody Fusion Protein, which is expected to be introduced to the market by the end of 2014. Then supply capacity of domestic monoclonal antibody agents will be further enhanced.

With advancement of monoclonal antibody technology, incoming expiry date for patents of some blockbuster monoclonal antibody agents and bright future for monoclonal antibody, Livzon Pharmaceutical Group, Walvax Biotechnology, Hualan Biological Engineering, Shanghai Fosun Pharmaceutical and other companies invested heavily to enter monoclonal antibody market, and multiple products have entered stage of pre-preclinical or clinical research.

View All Upcoming Market Research Reports

In Sept. 2014, Hualan Biological Engineering submitted clinical applications for its three monoclonal antibody generic drugs, namely, trastuzumab, bevacizumab and rituximab; In Aug. 2014, Walvax Biotechnology’s recombinant anti-tumor necrosis factor-? fully human monoclonal antibody injection obtained clinical trial permission issued by Korean Food and Drug Administration (KFDA); In Apr. 2014, Shanghai Fosun Pharmaceutical formally received clinical trial permission approved and issued by CFDA for recombinant human-mouse chimeric anti-CD20 monoclonal antibody injection (rituximab monoclonal antibody genetic drug).

Related Reports

Regenerative Medicine Market (Bone And Joint) (By Technology - Stem Cell Therapy, Biomaterial And Tissue Engineering; By Applications - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products And Others) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

View Full Report

U.S. National Institute of Health stated that regenerative medicine is the process of creating functional tissue to repair and replace tissue or organ which has lost their function due to damage, congenital defects, disease and age. Moreover, it has included stem cell therapy, tissue engineering and biomaterial under the umbrella of regenerative medicine. Regenerative medicine has wide areas of application such as cardiovascular, neurology, orthopedic and musculoskeletal diseases and disorders. The global market for regenerative medicine bone and joint application is dominated by various bone graft substitute in 2012. However, it is expected that tissue engineering will become a lucrative market in future. Factors such as growing geriatric population, favorable government support and increasing bone and joint reconstructive surgeries accentuate growth of the global regenerative medicine bone and joint application market.

Download Detail Report With Complete TOC

This research report explains various advancements occurring in this market and analyzes the global regenerative medicine (bone and joint) market by technology and application. The regenerative medicine bone and joint application market by technology is further segmented into stem cell therapy, biomaterials and tissue engineering. Likewise, on basis of application the global regenerative medicine (bone and joint) market is segmented as bone graft substitutes, osteoarticular diseases, allogenic bones, autogenic bone and others.

Global Bioinformatics Market (By Platforms, Tools And Services And By Applications: Preventive Medicine, Molecular Medicine, Gene Therapy Drug Development And Others) - Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020

View Full Report With Complete TOC

Perpetually advancing information technology (IT) and thereby expansion of application area of information technology into biotechnology and life science industry is escalating the growth of the bioinformatics market globally. Bioinformatics is widely used in recording, processing, and converting the data obtained from research and development activities related to life sciences namely, biotechnology, biopharmaceutical, pharmaceutical and agricultural fields; into computerized digital data that can be later used to expedite further research. This report covers the market analysis for various platforms, tools, and services commercially available in bioinformatics technology that helps deliver advanced information technology to ever growing life science fields such as molecular biology, genetics, biotechnology, biopharmaceuticals, and other life sciences.

Download Detail Report With Complete TOC

This research report provides a detailed analysis of the global bioinformatics market and helps in understanding the various driving factors for the growth of the market. The market overview section of bioinformatics market report includes market dynamics and trends, which are further divided into factors such as drivers, restraints, and opportunities that influence the current nature and future status of bioinformatics market globally. These factors together give a thorough analysis of the overall competitive scenario in the global bioinformatics market. Impact factors such as market attractiveness analysis (by geography), market share analysis by key players and Porter’s five forces (bargaining power of suppliers, bargaining power of buyers, threat of substitutes, threat of new entrants and competitive rivalry) analysis have also been explained in the market overview section of the report. Further, this report includes average selling price analysis (in terms of USD) and value chain analysis of bioinformatics market.

Global And China Stem Cell Industry Report, 2014-2017

View Full Report With Complete TOC

Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients.

Download Detail Report With Complete TOC

The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out.

About is the most comprehensive collection of market research reports. services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.